Key Points. Statin use significantly improves overall and progression-free survival in CLL/SLL patients treated with ibrutinbNo significant increase in sev
🫠 Tweep 2010 – 2021 🦣 https://t.co/KuAtJkryhw 🧵https://t.co/1WZzdUtUPy
In this issue of Blood, Courtois et al present compelling preclinical data in support of a therapeutic role for coinhibition of the interleukin-7 receptor
Key PointsAOC in postpartum bleeding is caused by an excess of dysregulated plasmin generation leading to hyperfibrinolysis.Excessive plasmin causes fibrin
In this issue of Blood, Zhao et al report excellent overall responses and acceptable safety of a first-in-class JAK/ROCK inhibitor in a prospective phase 1
Key PointsADAMTS13 can be proteolytically degraded by hemostatic proteases, which may reduce its capacity to regulate VWF.Protease-resistant ADAMTS13 is st
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. In the current era of molecular profiling and newer treatments, cell-of-origin (COO)…
Recent molecular and diagnostic advances in acute myeloid leukemia (AML) have led investigators and clinicians to further categorize patients in different
Disclosures. Koura:BMS: Consultancy, Research Funding. Hamdan:Kite: Speakers Bureau. Goodman:Seattle Genetics: Consultancy. Tanaka:Gilead Sciences: Consult
Abstract. Crizanlizumab and voxelotor were several of the first drugs to receive the US Food and Drug Administration (FDA) approval for sickle cell disease
Abstract. Between 2019 and 2021, the American Society of Hematology (ASH) developed clinical guidelines for managing sickle cell disease (SCD), covering ac
